Anti-glycation and anti-albuminuric effects of GLY-230 in human diabetes

Laurence Kennedy, Maria Pilar Solano, Luigi Meneghini, Margaret Lo, Margo P. Cohen

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background/Aims: Inhibiting nonenzymatic glycation with GLY-230 lowers glycated albumin without affecting hyperglycemia and ameliorates renal dysfunction in the db/db mouse, but the effects of this compound in man have not been assessed. We report results from the first clinical trial in patients with diabetes of this new glycation inhibitor. Methods: 21 diabetic men were randomly assigned to receive a total dose of 250, 500 or 750 mg of GLY-230 or placebo (1:1:1:1.2 ratio) daily for 14 days to evaluate safety and the effect of drug on plasma concentrations of glycated albumin and on urinary albumin. Results: GLY-230 dose-responsively decreased glycated albumin in all participants, in whom HbA1c did not change. Among participants exhibiting microalbuminuria at baseline, mean albumin excretion significantly decreased in patients receiving GLY-230 (μg albumin/mg creatinine = 61.4 ± 15.8 and 29.8 ± 10.4 at baseline and completion, respectively; p = 0.001), but not placebo. There were no serious adverse events or laboratory abnormalities, and all safety parameters remained within normal limits. Conclusions: This first-in-diabetic man study indicates that GLY-230 lowers glycated albumin and that this decrease is associated with a reduction in urine albumin excretion in patients with preexisting microalbuminuria. These data encourage further evaluation of GLY-230 in diabetic renal dysfunction.

Original languageEnglish (US)
Pages (from-to)110-116
Number of pages7
JournalAmerican Journal of Nephrology
Volume31
Issue number2
DOIs
StatePublished - Feb 2010

Fingerprint

Albumins
Placebos
Kidney
Safety
Hyperglycemia
2-(3-chlorophenylamino)phenylacetic acid
Creatinine
Clinical Trials
Urine
glycosylated serum albumin
Pharmaceutical Preparations

Keywords

  • Clinical studies
  • Diabetic nephropathy
  • Glycated albumin
  • Glycation inhibitor
  • Microalbuminuria

ASJC Scopus subject areas

  • Nephrology

Cite this

Anti-glycation and anti-albuminuric effects of GLY-230 in human diabetes. / Kennedy, Laurence; Pilar Solano, Maria; Meneghini, Luigi; Lo, Margaret; Cohen, Margo P.

In: American Journal of Nephrology, Vol. 31, No. 2, 02.2010, p. 110-116.

Research output: Contribution to journalArticle

Kennedy, Laurence ; Pilar Solano, Maria ; Meneghini, Luigi ; Lo, Margaret ; Cohen, Margo P. / Anti-glycation and anti-albuminuric effects of GLY-230 in human diabetes. In: American Journal of Nephrology. 2010 ; Vol. 31, No. 2. pp. 110-116.
@article{07db106a1da04797bfd29c30fdd383c0,
title = "Anti-glycation and anti-albuminuric effects of GLY-230 in human diabetes",
abstract = "Background/Aims: Inhibiting nonenzymatic glycation with GLY-230 lowers glycated albumin without affecting hyperglycemia and ameliorates renal dysfunction in the db/db mouse, but the effects of this compound in man have not been assessed. We report results from the first clinical trial in patients with diabetes of this new glycation inhibitor. Methods: 21 diabetic men were randomly assigned to receive a total dose of 250, 500 or 750 mg of GLY-230 or placebo (1:1:1:1.2 ratio) daily for 14 days to evaluate safety and the effect of drug on plasma concentrations of glycated albumin and on urinary albumin. Results: GLY-230 dose-responsively decreased glycated albumin in all participants, in whom HbA1c did not change. Among participants exhibiting microalbuminuria at baseline, mean albumin excretion significantly decreased in patients receiving GLY-230 (μg albumin/mg creatinine = 61.4 ± 15.8 and 29.8 ± 10.4 at baseline and completion, respectively; p = 0.001), but not placebo. There were no serious adverse events or laboratory abnormalities, and all safety parameters remained within normal limits. Conclusions: This first-in-diabetic man study indicates that GLY-230 lowers glycated albumin and that this decrease is associated with a reduction in urine albumin excretion in patients with preexisting microalbuminuria. These data encourage further evaluation of GLY-230 in diabetic renal dysfunction.",
keywords = "Clinical studies, Diabetic nephropathy, Glycated albumin, Glycation inhibitor, Microalbuminuria",
author = "Laurence Kennedy and {Pilar Solano}, Maria and Luigi Meneghini and Margaret Lo and Cohen, {Margo P.}",
year = "2010",
month = "2",
doi = "10.1159/000259897",
language = "English (US)",
volume = "31",
pages = "110--116",
journal = "American Journal of Nephrology",
issn = "0250-8095",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Anti-glycation and anti-albuminuric effects of GLY-230 in human diabetes

AU - Kennedy, Laurence

AU - Pilar Solano, Maria

AU - Meneghini, Luigi

AU - Lo, Margaret

AU - Cohen, Margo P.

PY - 2010/2

Y1 - 2010/2

N2 - Background/Aims: Inhibiting nonenzymatic glycation with GLY-230 lowers glycated albumin without affecting hyperglycemia and ameliorates renal dysfunction in the db/db mouse, but the effects of this compound in man have not been assessed. We report results from the first clinical trial in patients with diabetes of this new glycation inhibitor. Methods: 21 diabetic men were randomly assigned to receive a total dose of 250, 500 or 750 mg of GLY-230 or placebo (1:1:1:1.2 ratio) daily for 14 days to evaluate safety and the effect of drug on plasma concentrations of glycated albumin and on urinary albumin. Results: GLY-230 dose-responsively decreased glycated albumin in all participants, in whom HbA1c did not change. Among participants exhibiting microalbuminuria at baseline, mean albumin excretion significantly decreased in patients receiving GLY-230 (μg albumin/mg creatinine = 61.4 ± 15.8 and 29.8 ± 10.4 at baseline and completion, respectively; p = 0.001), but not placebo. There were no serious adverse events or laboratory abnormalities, and all safety parameters remained within normal limits. Conclusions: This first-in-diabetic man study indicates that GLY-230 lowers glycated albumin and that this decrease is associated with a reduction in urine albumin excretion in patients with preexisting microalbuminuria. These data encourage further evaluation of GLY-230 in diabetic renal dysfunction.

AB - Background/Aims: Inhibiting nonenzymatic glycation with GLY-230 lowers glycated albumin without affecting hyperglycemia and ameliorates renal dysfunction in the db/db mouse, but the effects of this compound in man have not been assessed. We report results from the first clinical trial in patients with diabetes of this new glycation inhibitor. Methods: 21 diabetic men were randomly assigned to receive a total dose of 250, 500 or 750 mg of GLY-230 or placebo (1:1:1:1.2 ratio) daily for 14 days to evaluate safety and the effect of drug on plasma concentrations of glycated albumin and on urinary albumin. Results: GLY-230 dose-responsively decreased glycated albumin in all participants, in whom HbA1c did not change. Among participants exhibiting microalbuminuria at baseline, mean albumin excretion significantly decreased in patients receiving GLY-230 (μg albumin/mg creatinine = 61.4 ± 15.8 and 29.8 ± 10.4 at baseline and completion, respectively; p = 0.001), but not placebo. There were no serious adverse events or laboratory abnormalities, and all safety parameters remained within normal limits. Conclusions: This first-in-diabetic man study indicates that GLY-230 lowers glycated albumin and that this decrease is associated with a reduction in urine albumin excretion in patients with preexisting microalbuminuria. These data encourage further evaluation of GLY-230 in diabetic renal dysfunction.

KW - Clinical studies

KW - Diabetic nephropathy

KW - Glycated albumin

KW - Glycation inhibitor

KW - Microalbuminuria

UR - http://www.scopus.com/inward/record.url?scp=70449650467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449650467&partnerID=8YFLogxK

U2 - 10.1159/000259897

DO - 10.1159/000259897

M3 - Article

C2 - 19923796

AN - SCOPUS:70449650467

VL - 31

SP - 110

EP - 116

JO - American Journal of Nephrology

JF - American Journal of Nephrology

SN - 0250-8095

IS - 2

ER -